UK Diabetes Therapeutics Market Report 2022 to 2030

UK Diabetes Therapeutics Market Analysis

$ 3999

The UK diabetes therapeutics market is expected to grow from $3.74 Bn in 2022 to $6.77 Bn in 2030 with a CAGR of 7.7% for the forecasted year 2022-30. The rising incidence of diabetes and the subsequent demand for new and innovative treatment options for diabetes in the UK is driving the growth of the market. The UK diabetes therapeutics market is segmented by type, application, drug, route of administration, and distribution channel. Tanner Pharma, Bracco, and AstraZeneca are the major players in the UK diabetes therapeutics market.

ID: IN10GBPH036 CATEGORY: Pharmaceuticals GEOGRAPHY: UK AUTHOR: Dr. Parul Choudhary

Buy Now

UK Diabetes Therapeutics Market Executive Analysis

The UK diabetes therapeutics market size is at around $3.74 Bn in 2022 and is projected to reach $6.77 Bn in 2030, exhibiting a CAGR of 7.7% during the forecast period. The UK will raise health capital spending by $0.3 Bn for 2023–24, but this is due to underspending in 2022–23 and does not amount to an overall increase. The Medicines Healthcare and Regulation Authority (MHRA) will look into collaborating with organizations in the US, Europe, and Japan and will offer straightforward and quick approval in the UK for goods authorized by these organizations. The most major cost pressure on the National Health Service (NHS) is pay, which is continuing to rise and will reduce its ability to spend under this agreement. The central GDP deflator forecast suggests that inflationary pressures in the healthcare sector may be greater than the government had anticipated.

Over the past 15 years, the number of diabetes diagnoses has doubled, and the UK now has nearly 4.1 Mn individuals with either type 1 or type 2 diabetes. 90% of people have type 2, which has elevated blood pressure and obesity as major risk factors. If current trends continue, Diabetes UK predicts that this figure could increase to 5.5 Mn. The most popular treatment for type 2 diabetes is metformin. It may assist in maintaining a healthy amount of blood sugar. Other blood sugar-lowering medications include gliclazide, glimepiride, alogliptin, linagliptin, pioglitazone, tablets that also help the heart pump blood throughout the body like dapagliflozin or empagliflozin, and injections like exenatide or liraglutide that lower blood sugar and aid in weight loss.

The three prescribed medications, canagliflozin (Invokana), dapagliflozin (Forxiga), and empagliflozin (Jardiance) are the new drugs for type 2 diabetes recommended by NICE. If a person is unable to take metformin, sulfonylurea, or pioglitazone and nutrition and exercise alone are not controlling their blood sugar levels, they can all be taken on their own. When metformin is not the right choice, this offers people with Type 2 diabetes and their healthcare team more options. Individuals with Type 2 diabetes may react differently to various medications. Thus, this guidance gives clinicians more options to personalize the care they deliver, which can significantly improve some individuals with Type 2 diabetes quality of life.

UK Diabetes Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers

Both type 1 and type 2 diabetes have been steadily on the rise in the UK. As a result, there is a rising need for diabetes medications. There is a higher chance of developing diabetes as the number of people over 65 rises. Additionally, this group has a propensity for having more comorbid conditions, which increases the demand for diabetes treatments. Significant strides have been made in the treatment of diabetes, including the development of novel insulin formulations and insulin delivery techniques as well as continuous glucose monitoring devices. Treatment options and patient outcomes have increased as a result of these developments which has resulted in the growth of the UK diabetes therapeutics market.

Market Restraints

The cost of treating diabetes can be high, especially for more recent methods of therapy. Patients may find it difficult to pay for care as a result, and the use of novel treatments may be restricted. In the upcoming years, the patents on several important diabetes medications are anticipated to expire. Price pressure could result from this as generic producers compete more fiercely thereby limiting the expansion of the UK diabetes therapeutics market.

Competitive Landscape

Key Players

CurePharma Pharmaceutical (GBR)
Kent Pharma (GBR)
Amicus Therapeutics (GBR)
Tanner Pharma (GBR)
Bracco (GBR)
AstraZeneca
Novartis
Novo Nordisk
Boehringer Ingelheim
Bristol-Myers Squibb
Eli Lilly
Merck
Sanofi

Healthcare Policies and Regulatory Landscape

In the UK, pharmaceuticals, blood establishments, advanced therapy medicinal products, and medical equipment are all governed by the Medicines and Healthcare Products Regulatory Agency (MHRA). The National Institute for Biological Standards and Control (NIBSC) and the Clinical Practice Research Datalink (CPRD) are also part of the MHRA's network of organizations that report to the Department of Health. All medicines and medical devices sold in the UK must be high-quality, safe, and efficient, according to the MHRA. The organization evaluates requests for marketing authorizations and keeps track of the security of medicines and gadgets after they hit the market. The MHRA also offers guidance on the safe and efficient use of medications and devices to the general public and healthcare workers. The goal of the MHRA is to safeguard the public's health through regulation, ensuring that drugs and devices have appropriate benefit-risk profiles. To advance public health by assisting users of these goods in understanding the advantages and risks of using them. To promote and facilitate the development of goods that will benefit people in order to enhance public health.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Diabetes Therapeutics Segmentation

By Type (Revenue, USD Billion):

Diabetes 1
Diabetes 2

By Application (Revenue, USD Billion):

Preventive
- Prediabetes
- Nutrition
- Obesity
- Lifestyle Management
Treatment/Care
- Diabetes
- Smoking Cessation
- Musculoskeletal Disorders
- Central Nervous System Disorders
- Cardiovascular Disease
- Medication Adherence
- Chronic Respiratory Disorders
- Gastrointestinal Disorders
- Rehabilitation
- Substance Use Disorders & Addiction Management

By Drug (Revenue, USD Billion):

Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drug
Combination Drug

By Route of Administration (Revenue, USD Billion):

Oral
Subcutaneous
Intravenous

By Distribution Channel (Revenue, USD Billion):

Online Pharmacies
Hospital Pharmacies
Retail Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.

We value your inquiry and offer free customization with every report to fulfil your exact research needs.

Yes, I have read the privacy policy

Tanner Pharma, Bracco, and AstraZeneca are the major players in the UK diabetes therapeutics market.

The UK diabetes therapeutics market is expected to grow from $3.74 Bn in 2022 to $6.77 Bn in 2030 with a CAGR of 7.7% for the forecasted year 2022-2030.

The UK diabetes therapeutics market is segmented by type, application, drug, route of administration, and distribution channel.